Announcements Trials
Browse Landscape

Phase

Phase 1 2Phase 2 1

Status

Completed 3

Sponsor Class

OTHER 2INDUSTRY 1

Study Type

Interventional 3

Sponsor

Cancer Type

Dermatologic 3Thoracic 1Head & Neck 1Genitourinary 1Gastrointestinal 1Breast 1

Conditions

Carcinoma, Non-Small-Cell Lung 193Lung Neoplasms 80Pancreatic Neoplasms 47Neoplasms 31Non-Squamous Non-Small Cell Lung Cancer 19Head and Neck Neoplasms 19Glioblastoma 19Adenocarcinoma of Lung 19Squamous Cell Carcinoma of Head and Neck 18Neoplasm Metastasis 17Gliosarcoma 17Brain Neoplasms 17Breast Neoplasms 16Rectal Neoplasms 13Colorectal Neoplasms 13Colonic Neoplasms 13Adenocarcinoma, Bronchiolo-Alveolar 13Carcinoma, Hepatocellular 11Carcinoma, Renal Cell 10Glioma 8Astrocytoma 8Salivary Gland Neoplasms 7Gallbladder Neoplasms 7Esophageal Neoplasms 7Carcinoma, Ovarian Epithelial 7Prostatic Neoplasms 6Ovarian Neoplasms 6Oligodendroglioma 6Fallopian Tube Neoplasms 6Carcinoma, Squamous Cell 6

Interventions

Ipilimumab 114pembrolizumab 95Nivolumab 91aldesleukin 86Interleukin-2 57Cyclophosphamide 54Dacarbazine 52Vemurafenib 39trametinib 37Temozolomide 37incomplete Freund's adjuvant 35fludarabine phosphate 35sargramostim 32dabrafenib 32fludarabine 26Bevacizumab 26Paclitaxel 22MART-1 Antigen 21Granulocyte-Macrophage Colony-Stimulating Factor 21montanide ISA 51 20Interferon-alpha 20Cisplatin 20Carboplatin 19Sorafenib 18Introns 17Biopsy 17cobimetinib 16Radiosurgery 16atezolizumab 15Radiotherapy 15

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Completed × Melanoma × Erlotinib Hydrochloride × Clear all
NCT00600496 2026-05-27

A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)

AstraZeneca

Phase 1 Completed
140 enrolled
BreastDermatologicGastrointestinalGenitourinaryThoracic

Breast Neoplasms, Colonic Neoplasms, Kidney Neoplasms, Lung Neoplasms, Melanoma, Neoplasms

NCT00405405 2025-05-06

Phase I of Biologics and Chemoradiation Therapy for Advanced Head and Neck Cancer

Thomas Jefferson University

Phase 1 Completed
13 enrolled
DermatologicHead & Neck

Head and Neck Neoplasms, Melanoma, Parotid Neoplasms, Thyroid Neoplasms

NCT00466687 2013-07-22

Erlotinib and Bevacizumab in Treating Patients With Stage IV Melanoma

Vanderbilt-Ingram Cancer Center

Phase 2 Completed
34 enrolled 10 charts
Dermatologic

Melanoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡